Source
Kevin M. Alexander, MD, eagerly awaits the presentation of new amyloid dataat the 2026 ACC meeting in New Orleans and is especially interested in the subgroup analyses from the ATTRibute-CM and HELIOS-B phase 3 clinical trials, focusing on biomarkers and long-term extension results.
Dr Alexander is also hoping for observational and real-world data related to multiple available ATTR therapies, and anticipates valuable educational content on imaging and its role in monitoring patients and informing treatment decisions for ATTR-CM.